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Lipoprotein(a) is a plasma lipoprotein and known cardiovascular risk factor, most recently 
implicated in the development of high-risk carotid atherosclerotic plaques without sig-
nificant carotid stenosis. We present a case of a young African-American female with 
recurrent embolic strokes of undetermined source. After our thorough investigation, we 
identified the link between a small, irregular plaque in the right internal carotid artery, and 
an extremely elevated plasma level of lipoprotein(a) as the source of her embolic strokes.
Keywords: stroke, embolic stroke of undetermined source, cryptogenic stroke, lipoprotein(a), carotid 
atherosclerosis, carotid stenting
Case RepoRt
We report a case of a 46-year-old female with a past medical history significant for multiple right-
sided cerebral ischemic events who was transferred from an outside hospital with acute left upper 
and lower extremity weakness. At the outside hospital, computed tomography (CT) imaging dem-
onstrated an acute middle cerebral artery infarct. Due to contraindications, she did not receive tissue 
plasminogen activator (tPA).
Upon transfer, magnetic resonance imaging (MRI) and magnetic resonance angiography (MRA) 
demonstrated occlusions in the right anterior cerebral artery and middle cerebral artery, and a focal, 
irregular plaque in the right internal carotid artery (ICA). Cerebral angiogram redemonstrated the 
plaque, but no immediate intervention was recommended due to non-hemodynamically significant 
stenosis of less than 20% (Figure 1).
The patient’s vitals, complete blood count, comprehensive metabolic panel, coagulation studies, 
and lipid panel were all within normal limits upon admission. The patient was placed on continu-
ous cardiac telemetry. Secondary prevention was optimized by the addition of clopidogrel to the 
standard secondary prevention she was already receiving prior to admission, which included aspirin 
and atorvastatin.
One week later, the patient complained of a new onset headache. With no history of headache, 
precautions were taken, and a repeat MRI revealed a new infarct in the right occipital lobe and 
frontal lobe.
Electrocardiographic, echocardiographic (including transesophageal echocardiogram), and 
neuroimaging studies exhibited no major-risk cardioembolic source. Hypercoagulability workup 
was negative except for an extremely elevated plasma lipoprotein(a) level (414 mg/dL). The patient 
underwent stent placement to stabilize her vulnerable ICA plaque. She was then discharged to an 
acute rehabilitation facility 2 days later in stable condition.
FIGURe 1 | Multiple embolic territory strokes secondary to irregular and vulnerable carotid atherosclerotic plaque. (a–H) Brain MRI scans from multiple 
ischemic events over multiple admissions. (I) Right carotid angiogram. Arrow indicates atherosclerotic plaque in right internal carotid artery.
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DIsCUssIoN
We describe a young African-American female who meets crite-
ria for recurrent embolic strokes of undetermined source (ESUS) 
(1). After thorough diagnostic investigation, as outlined by Nouh 
et al. (2), two pertinent abnormalities were found: a small, irregu-
lar plaque in the right ICA and an extremely elevated plasma level 
of lipoprotein(a) [Lp(a)].
Lipoprotein(a) is a known cardiovascular risk factor, 
but controversy surrounds its utility as a screening tool 
and our understanding of its pathological mechanisms 
(3). Lipoprotein(a) is a plasma lipoprotein consisting of a 
cholesterol-rich low-density lipoprotein (LDL) particle with 
one molecule of apolipoprotein B100 covalently linked via 
a disulfide bond to apolipoprotein(a) (3, 4). Plasma levels of 
Lp(a) are directly related to the variable copy number of kringle 
IV type 2 (KIV-2) repeats of the apolipoprotein(a) isoforms 
in the LPA gene (3, 4). Smaller isoforms of apolipoprotein(a) 
are associated with higher concentrations of Lp(a) (3, 5, 6). 
Lipoprotein(a) levels vary widely in humans, with up to 90% 
genetically determined via the LPA gene (6, 7). Individuals 
with smaller apolipoprotein(a) isoforms have roughly a twofold 
higher risk of ischemic stroke and coronary heart disease (5). 
Thus, there is a causal link evidenced by Mendelian randomiza-
tion between genetically determined elevated levels of Lp(a) 
and cardiovascular disease (3–5).
Two aspects of Lp(a) make it exceptionally interesting: first, 
the apolipoprotein(a) co-factor is structurally homologous to 
plasminogen, but without fibrinolytic activity; and second, the 
metabolism and distribution of Lp(a) differs from that of LDL 
(8, 9). Nevertheless, the physiologic function of Lp(a) remains 
elusive, although its atherogenicity is thought to be due to the 
interference of the fibrinolytic pathway among other interac-
tions (8).
Cerebral vascular disease, peripheral vascular disease, and 
most recently, carotid atherosclerosis have been associated 
with elevated serum levels of Lp(a) (8). These associations are 
independent of the levels of cholesterol and other traditional risk 
factors, such as age, gender, smoking, systolic blood pressure, 
antihypertensive medication use, diabetes mellitus, LDL choles-
terol, HDL cholesterol, and triglycerides (10–12).
Virani et  al. contend that elevated Lp(a) in African-
Americans may confer a higher risk for a cerebrovascular event 
than for a coronary vascular event (13). They found a positive 
correlation between Lp(a) levels and ischemic stroke at plasma 
levels greater than 30 mg/dL in the African-American popula-
tion (12, 13). Most recently, Zhao et al. identified that elevated 
Lp(a) levels were associated with high-risk carotid atheroscle-
rotic plaque features. Although these high-risk plaques were 
often seen in less severe carotid stenosis, they were vulnerable 
to embolization and were associated with an increased rate of 
strokes (14). In the ongoing CAPIAS study, which hopes to 
provide further insight into the role of non-stenosing carotid 
artery plaques, nearly half of the initially enrolled patients were 
found to have cryptogenic stroke as defined by TOAST criteria 
(15, 16).
The extreme plasma level of Lp(a) in combination with an 
irregular carotid plaque offered few therapeutic options for 
optimizing secondary prevention in the setting of recurrent 
ESUS. The promise Lp(a) holds is that, as an independent risk 
factor for cardiovascular disease, reducing elevated plasma levels 
will directly reduce cerebrovascular disease (1, 17). A promising 
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new class of lipid-lowering drugs are the proprotein convertase 
subtilisin/kexin type 9 (PCSK9) inhibitors. PCSK9 regulates 
the catabolism of Lp(a) by inhibiting Lp(a) internalization via 
the LDL receptor (18). In a pooled analysis of phase II trials, 
PCSK9 inhibition (via evolocumab) resulted in statistically 
significant dose-related reductions in Lp(a), although no results 
have indicated a reduction of cerebrovascular events (19). And 
more recently, PCSK9 has been found complexed to Lp(a) 
particles in humans with elevated Lp(a) levels (20). It remains 
to be determined whether lowering Lp(a) levels directly will 
result in lower cardiovascular event rates, which may provide an 
additional therapeutic mechanism: antisense oligonucleotides 
directed against apo(a) (17). Possibly, the most compelling evi-
dence comes from the Pro(a)Life Study Group in which chronic 
lipoprotein apheresis was shown to reduce the risk of recurrent 
cardiovascular events (and the need for carotid stenting) over a 
2-year period in patients on maximally tolerated lipid-lowering 
therapy (21).
While long-term consideration of our patient’s chronically 
elevated plasma Lp(a) level is critical, acute stabilization of the 
irregular and vulnerable carotid plaque was deemed most impor-
tant due to the rapid timeline of embolic stroke recurrence. The 
patient was on aspirin upon admission, but no anticoagulation, 
consistent with recommendations from the WARSS trial (22). 
Although there is evidence in a subgroup analysis that warfarin 
may be more efficacious than aspirin among patients with crypto-
genic stroke who did not have hypertension and did have embolic 
infarcts on neuroimaging, we did not initiate anticoagulation 
due to concern for an increase in major hemorrhages (22, 23). 
Currently, two trials are underway to investigate the benefit and 
risk of anticoagulation with direct oral anticoagulants (DOACs) 
compared with aspirin in patients with embolic stroke of unde-
termined source (24, 25). Due to the lack of currently available 
therapeutic options and probable association to the recurrent 
strokes, a decision was made to stabilize the carotid clot via 
stenting.
CoNCLUsIoN
Considering the clinical picture, imaging, and accompanying 
laboratory data, it is probable that the irregular and vulnerable 
carotid atherosclerotic plaque contributed to recurrent ESUS. 
Thus, it is likely that Lp(a), in contributing to the development 
of the plaque, indirectly triggered these embolic infarctions. We 
suggest measuring Lp(a) in the workup of recurrent embolic stroke 
of undetermined source in the setting of non-hemodynamically 
significant carotid stenosis in young African-American individu-
als. Further study will hopefully determine the pathogenic mecha-
nism of elevated Lp(a) plasma levels in order to optimize current 
therapies and yield new potential therapeutic targets. The recent 
introduction of PCSK9 inhibitors offers clinicians a novel thera-
peutic approach to reduce Lp(a) levels, but more research needs to 
be undertaken to evaluate cerebrovascular outcomes. Results from 
current randomized controlled trials in patients with ESUS will 
ideally illustrate the best therapeutic options in the interim (24, 25).
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